Transcend Therapeutics' Procysteine to enter Phase III for ARDS in early 1997 -- IPO prospectus.

Executive Summary

TRANSCEND THERAPEUTICS PROCYSTEINE TO ENTER PHASE III TRIALS for treatment of acute respiratory distress syndrome in the first quarter of 1997, the company forecasts in an Aug. 22 prospectus for an initial public offering. Procysteine treats diseases associated with oxidative damage, the prospectus states, describing it as "a system for introducing into cells the amino acid cysteine, an essential building block of glutathione," one of the body's principal mechanisms for neutralizing the highly reactive toxic molecules known as reactive oxygen species, according to Transcend.